Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma

被引:70
作者
Guo, WJ
Yu, EX
Liu, LM
Li, L
Chen, Z
Lin, JH
Meng, ZQ
Feng, Y
机构
[1] Shanghai Med Univ 2, Dept Oncol, Xinhua Hosp, Dept Oncol, Shanghai 200092, Peoples R China
[2] Fudan Univ, Canc Hosp, Shanghai 200032, Peoples R China
关键词
D O I
10.3748/wjg.v9.i8.1697
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with radiotherapy for unresectable large hepatocellular carcinoma (HCC). METHODS: From June 1994 to June 1999, a total of 76 patients with large unresectable HCC were treated with TACE followed by external-beam irradiation. 89 patients with large HCC, who underwent TACE alone during the same period, served as the control group. Clinical features, therapeutic modalities, acute effects and survival rates were analyzed and compared between TACE plus irradiation group and TACE alone group. A multivariate analysis of nine clinical variables and one treatment variable (irradiation) was performed by the Cox proportional hazards model. RESULTS: The clinical features and therapeutic modalities except irradiation between the two groups were comparable (P>0.05). The objective response rate (RR) in TACE plus irradiation group was higher than that in TACE alone group (47.4% vs 28.1%, P<0.05). The overall survival rates in TACE plus irradiation group (64.0%, 28.6%, and 19.3% at 1, 3, 5 years, respectively) were significantly higher than those in TACE alone group (39.9%, 9.5%, and 7.2%, respectively, P=0.0001). Cox proportional hazards model analysis showed that tumor extension and Child grade were significant and were independent negative predictors of survival, while irradiation was an independent positive predictor of survival. CONCLUSION: TACE combined with radiotherapy is more effective than TACE alone, and is a promising treatment for unresectable large HCC.
引用
收藏
页码:1697 / 1701
页数:5
相关论文
共 47 条
[1]  
Allgaier HP, 1998, INT J CANCER, V79, P601, DOI 10.1002/(SICI)1097-0215(19981218)79:6<601::AID-IJC8>3.0.CO
[2]  
2-F
[3]   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[4]   Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric analysis and implication [J].
Cheng, JCH ;
Wu, JK ;
Huang, CM ;
Liu, HS ;
Huang, DY ;
Cheng, SH ;
Tsai, SY ;
Jian, JJM ;
Lin, YM ;
Cheng, TI ;
Horng, CF ;
Huang, AT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (01) :156-162
[5]   Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization [J].
Cheng, JCH ;
Chuang, VP ;
Cheng, SH ;
Lin, YM ;
Cheng, TI ;
Yang, PS ;
Jian, JJM ;
You, DL ;
Horng, CF ;
Huang, AT .
INTERNATIONAL JOURNAL OF CANCER, 2001, 96 (04) :243-252
[6]   A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma [J].
Cheng, SH ;
Lin, YM ;
Chuang, VP ;
Yang, PS ;
Cheng, JCH ;
Huang, AT ;
Sung, JL .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (10) :1025-1033
[7]  
Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8
[8]   Hepatocellular carcinoma - An epidemiologic view [J].
El-Serag, HB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 35 (05) :S72-S78
[9]   Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States [J].
El-Serag, HB ;
Mason, AC ;
Key, C .
HEPATOLOGY, 2001, 33 (01) :62-65
[10]   Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe [J].
Faivre, J ;
Forman, D ;
Estève, J ;
Obradovic, M ;
Sant, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2184-2190